Articles tagged with Cancer Immunology
Scientists have engineered a herpes virus to activate pathways in T cells, enhancing their ability to fight cancer. The approach uses proteins from the herpes virus to recruit enzymes that sustain T cell function in tumors.
Researchers identify five distinct immunotypes in tongue squamous cell carcinoma, shedding light on why current immunotherapies fail. The study's findings highlight the need for immune-based assessments to guide treatment decisions and suggest a new approach to personalized medicine.
The review highlights three key regulatory layers of T-cell plasticity: cellular signals, metabolic reprogramming, and physical and biological factors. Innovative therapeutic strategies, such as immune checkpoint therapy and adoptive cell therapy, aim to restore T-cell function and enhance antitumor immunity.
Researchers from City of Hope will present novel cancer treatment approaches and combinations, including innovative combination therapies for breast, genitourinary, and gastrointestinal cancers. Additionally, they'll discuss the safety of readministering trastuzumab-deruxtecan to metastatic breast cancer patients with low-grade lung co...
Researchers at MD Anderson Cancer Center have made significant discoveries in three key areas of cancer care. In a study on sickle cell disease, the team found that the disorder can suppress immunity by altering DNA structure in CD8+ T cells, leading to potential strategies for improving immunotherapy responses. Meanwhile, a biomarker-...
Researchers found that aging impairs CAR-T cell function and antitumor activity due to lower NAD levels. Rejuvenating aged cells with NAD-boosting compounds improves their effectiveness.
Researchers at The University of Osaka found that localized oxygen deficiency in colon tumors can promote tumor growth by transforming normal fibroblasts into inflammatory fibroblasts. These altered cells release factors that help tumors grow, offering a potential new target for cancer therapy.
A study found that blood cancer survivors are more likely to face financial hardship and take fewer medications due to high-cost immunotherapy treatments. Financial strain affects both Medicare-insured and uninsured patients, highlighting the need for better financial support and policy strategies.
The University of Texas at Arlington's nursing and physics team has developed a system to study alpha radiation, improving the effectiveness of radiation therapy. The team's research was recognized with the Best in Physics award at the American Association of Physicists in Medicine's annual meeting.
Researchers found that phospholipids in ascites fluid disrupt immune cell function, particularly NK cells, leading to impaired anti-tumor activity. Blocking these lipids can restore NK cell activity, providing a promising therapeutic target.
Researchers at MD Anderson Cancer Center have made breakthroughs in understanding pancreatic cancer metastases and identifying potential biomarkers for treatment-resistant pancreatic cancer. A comprehensive spatial map provides insights into lineage shifts in cancer cells transitioning from primary tumors to organ-specific metastases.
This study compares laser-guided technology to conventional manual percutaneous lung biopsy, finding that laser-guided technology can reduce operational time and needle adjustments. However, it did not reduce complication rates or improve pathological diagnosis accuracy compared to traditional methods.
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
A team of researchers has identified a novel oncometabolite that accumulates in tumors and impairs immune cells' ability to fight cancer. The study highlights how the metabolic environment of tumors influences T cell function, opening new possibilities for improving cancer immunotherapy by targeting tumor metabolism.
Berger has made significant contributions to cancer epigenetics and tumor biology. Her work has elucidated key mechanisms of p53 regulation and immune cell epigenetics, advancing our understanding of cancer biology.
Researchers at Cold Spring Harbor Laboratory have identified a connection between the brain and immune system responsible for cachexia-related apathy. By targeting specific neurons and immune system proteins, they hope to improve cancer patients' quality of life and tolerance for treatments.
A recent study by researchers at TUM has discovered that the body produces special T cells predisposed to exhaustion even in early infection phases of moderate diseases. This finding expands our understanding of immune response mechanisms and could help control the immune system in cancer patients or weaken excessive defenses.
The project aims to enhance CTC detection sensitivity and specificity for clinical needs in cancer early screening, diagnosis and treatment. The team will develop an integrated system covering CTC counting, classification and downstream detection of CTC proteins and genes.
Researchers have discovered double negative memory B cells, a novel subset of immune cells that are more dysfunctional when in close contact with tumors. These cells may be a useful diagnostic marker and a potential target for developing new immunotherapies.
Researchers discover mitochondrial transfer between cancer cells and immune cells as a key immune evasion strategy. Cancer cells can reshape the tumor microenvironment to weaken tumor-infiltrating lymphocytes, and mitochondria play a significant role in this process.
Researchers at the University of Melbourne have identified a rare type of immune cell, called stem-like T cells, that holds the key to maintaining powerful, long-term immune responses. ID3+ T cells have the remarkable ability to resist burnout and maintain a powerful immune response over time.
Researchers have discovered a key strategy through which persister cells evade the immune response and resist cancer treatments. Inhibiting an epigenetic mechanism could unlock inflammatory genes and compromise persister cell viability.
Scientists at Salk Institute discovered that removing bile acid-creating protein BAAT and adding bile acid UDCA controls tumor growth in mice with liver cancer. UDCA supplements may be a quick solution to improving liver cancer patient outcomes.
Scientists at Goethe University Frankfurt have discovered a new way to tailor natural killer cells to target leukemia cells, improving their efficacy. The researchers used CRISPR/Cas9 gene editing to disable an immune checkpoint, allowing the modified cells to attack cancer cells more effectively.
Researchers at Salk Institute establish a novel framework for the relationship between nutrition and cell identity. They found that a nutritional switch from acetate to citrate plays a key role in determining T cell fates, shifting them from active effector cells to exhausted cells.
Researchers at NYU Langone Health discovered two ways cancer cells evade chemotherapy's effects: by slowing down pyrimidine synthesis and activating anti-apoptotic proteins. This better understanding could lead to more effective combination therapies and diagnostic tests, ultimately improving patient outcomes.
Researchers at Michigan Medicine found that SLC13A3 transporter impairs tumor immunity by endowing ferroptosis resistance. This discovery suggests a potential target for improving immunotherapy responses in cancer patients.
A new mechanism has been found by which tumor cells escape the immune system, involving a protein called IRGQ. Studies have shown that suppressing IRGQ can trigger a stronger immune response against cancer cells, leading to improved survival rates in liver cancer patients.
Researchers at Penn State College of Medicine have re-engineered natural killer immune cells with blue light-activated protein function, allowing them to infiltrate and kill solid tumor spheroids. The technology has shown promising results in killing breast cancer and melanoma cells within seven days.
Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells that can be switched on and off with existing drugs, improving safety and efficacy in solid tumors. The design and preclinical evaluation of the CAR-T cells addresses the challenges of traditional therapy.
The developed pipeline, NeoDisc, integrates molecular and genetic analyses of tumors and utilizes artificial intelligence algorithms to identify personalized neoantigens for vaccine design. Researchers also show that NeoDisc provides a more accurate selection of effective cancer antigens than current computational tools.
A new method to construct protein complex-based therapeutics has been discovered using a polymer cloak, which stabilizes the delivery of protein complexes and enables tumor-targeted immunomodulation. The study presents an IL-15 nanosuperagonist with enhanced efficacy and specificity, promising a safer therapy for cancer treatment.
A phase 1b/2 clinical trial found a combination of immunotherapy and FGFR inhibitor to be safe and tolerable in patients with locally advanced or metastatic bladder cancer. The treatment showed increased response rates, including 54% for patients with high FGFR mRNA expression.
A recent study by Dr. Esteban Ballestar's group identifies an immune cell population that is more effective in responding against cancer cells under hypoxia. Macrophages undergo changes that enhance their ability to trigger an immune response, leading to better patient outcomes in bladder and ovarian cancers.
A new study published in Frontiers in Immunology reveals that certain food proteins like milk and meat can help keep gut tumors from growing by triggering the intestinal immune system. This discovery has potential clinical implications for patients with gastrointestinal conditions.
A study by IRB Barcelona researchers has identified five independent factors that determine patients' response and survival after receiving checkpoint inhibitors, a type of immunotherapy. These findings provide a framework for current and future biomarkers of immunotherapy response and could lead to more accurate patient classification.
Researchers have found that natural killer cells instinctively recognize and attack the XPO1 protein, which drives cancer growth. By targeting this protein, scientists may be able to activate more killer cells to destroy cancer cells. The study suggests that this approach could lead to personalized cancer treatment with less side effects.
Researchers have identified a shared molecular mechanism between pregnancy and cancer that suppresses the immune system. Progesterone was found to play a key role in this process, with blocking its signaling slowing down cancer growth in mice and activating the immune response.
Researchers develop optogenetic system to precisely target cancer cells using light, inducing inflammatory cell death and triggering immune response. The approach aims to modulate the immune suppressive environment around cancer cells, helping T cells recognize and attack the disease.
Researchers from Aarhus University have discovered that combining a cancer-fighting viral agent with the drug 4-Octyl-Itaconate (4-OI) enhances its effectiveness in treating resistant cancers. This groundbreaking finding may lead to new treatment options for previously incurable diseases.
A new immunotherapy approach employs a two-pronged attack against solid tumors to boost the immune system's ability to target and eliminate cancer cells. By combining CV1-producing T cells with cancer-targeting antibodies, researchers improved macrophage consumption of tumor cells, suggesting a potential solution to treatment challenges.
Researchers at University of Turku have discovered a novel RNA that controls the development and function of regulatory T cells. This finding may enable the development of precision medicine treatments for autoimmune diseases and cancer.
A team of researchers from Xi'an Jiaotong-Liverpool University has engineered a short sequence of artificial DNA to target the mutant protein p53-R175H, linked to lung, colorectal, and breast cancers. The new molecule, dp53m, inhibits cancer cell growth and increases sensitivity to chemotherapy agent cisplatin.
Fred Hutch researchers present progress in treating metastatic cancer with novel therapies, including a Phase II study testing TNF-a inhibitors for castration-resistant prostate cancer. The center also explores improving hospice access and using machine learning with CAR T-cell therapy to enhance patient outcomes.
Researchers found that ARID1A mutation renders tumors sensitive to immunotherapy by triggering an antiviral immune response. This could lead to improved patient outcomes and the development of targeted therapies.
Researchers developed a predictive model, TRTpred, to identify the most potent cancer killing immune cells using artificial intelligence. The model achieved 90% accuracy in identifying tumor-reactive T cells and can be applied to personalized cancer treatments.
Researchers have discovered a new immunotherapy approach to overcome resistant leukemia by targeting the mutated TP53 gene. Combining pharmacological therapies with genetically engineered CAR T-cells increases effectiveness against cancer cells, offering promising strategies for patients with resistant disease.
A new DNA origami platform, DoriVac, enables precise spacing of adjuvant molecules and a variety of antigens to enhance anti-tumor responses. The vaccine demonstrated enhanced efficacy in controlling tumor growth and prolonging survival in mice, synergizing with immune checkpoint inhibitors.
A novel reporter cell experimental system enables the visualization of sequential changes during endothelial-mesenchymal transition (EndoMT) induced by transforming growth factor-β. Researchers identified CD40 as a potential partial EndoMT marker, which suppresses the transition from partial to full EndoMT.
Lung adenocarcinoma cells manipulate macrophage lipid metabolism to drive tumor progression. This exploitation of immune cells' metabolic pathways may be targeted with statins, improving lung cancer treatments.
The Vilcek Foundation has awarded $250,000 to four immigrant scientists for their pioneering work in biomedical science. Luciano Marraffini, Gerta Hoxhaj, Tomasz Nowakowski, and Takanori Takebe are recognized for their contributions to cancer research, pluripotent stem cells, and CRISPR-Cas systems.
Researchers have found that some tumors release a protein with a virus-like structure, triggering an out-of-control immune reaction that can damage brain cells. The immune system targets this protein as if it were a foreign invader, leading to rapid-onset memory loss and cognitive deficits.
Researchers discovered that cisplatin chemotherapy enhances the immune system's ability to fight bladder cancer by modulating the immune response and damaging DNA in cancer cells. This approach may lead to durable disease control in a subset of patients with metastatic bladder cancer.
Researchers provide new insights into STING's function in innate immunity, revealing its role as a scaffold that activates TBK1. They also found that cholesterol plays a crucial role in STING clustering and activation, offering a potential target for treating diseases associated with STING inflammation.
Researchers uncover a link between hyperactive Rac2 and human immune deficiency, shedding light on a mysterious condition. They also find promise in using cellular cannibalism to enhance cancer treatment.
Researchers have found a way to control MYC's hyperactivity using a peptide compound with sub-micro-molar affinity. This breakthrough offers hope for more effective treatments for cancer patients.
Gladstone scientists have created an intricate map of how the immune system functions, examining the detailed molecular structures governing human T cells. This study will accelerate the development of new and better therapies for cancer and autoimmune diseases.
A phase 1 clinical trial demonstrates the efficacy of third-generation anti-CD19 CAR T-cells in treating relapsed or refractory B-cell non-Hodgkin lymphomas without causing neurotoxicity. The study also shows a robust response rate of 52% and improved safety profile compared to previous CAR T-cell therapies.
Studies at single-cell resolution reveal significant tumor cell heterogeneity and an immune-evasive environment that contributes to treatment resistance in T follicular helper cell lymphomas. A novel marker, PLS3, is also identified as a key player in this process.
Researchers confirm that pancreatic cancer triggers a response in the immune system, but T cells struggle to infiltrate tumors. This finding could guide future treatment development for pancreatic ductal adenocarcinoma (PDAC), a deadly form of pancreatic cancer.